Table 1.
Antiretroviral Agents and Hepatitis C Virus (HCV) Protease Inhibitors (PIs)
| Antiretroviral Agents |
|||
|---|---|---|---|
| HCV PI | Evaluated in Clinical Trials | Coadministration Not Recommended | Prescribing Information |
| BOC | Tenofovir/emtricitabine or tenofovir/lamivudine, plus atazanavir/ritonavir or raltegravir | Efavirenz | BOC concentrations decreased with ritonavir, darunavir /ritonavir, and lopinavir/ritonavir. |
| AIDS Clinical Trials Group 5294 may permit use of additional antiretroviral agents. | BOC decreased concentrations of ritonavir, atazanavir/ritonavir, darunavir/ritonavir, and lopinavir/ritonavir. These medications can lose effectiveness when coadministered; close monitoring is recommended. | ||
| Plasma trough concentrations of BOC were decreased when BOC was coadministered with efavirenz, indicating a possible loss of therapeutic effect; avoid combination. | |||
| TEL | Tenofovir/emtricitabine or tenofovir/lamivudine, plus atazanavir/ritonavir; coadministration with efavirenz is possible with a higher dose of TEL (1125 mg 3 times daily) | Darunavir/ritonavir, fosamprenavir/ritonavir, and lopinavir/ritonavir | Concomitant administration of TEL and atazanavir/ritonavir resulted in reduced steady-state TEL exposure, while steady-state atazanavir exposure was increased. |
| Coadministration of TEL and raltegravir increases raltegravir exposure by 31%, but dose adjustment not necessary. | Concomitant administration of TEL and darunavir/ritonavir resulted in reduced steady-state exposures to TEL and darunavir. Coadministration is not recommended. | ||
| Concomitant administration of TEL and fosamprenavir/ritonavir resulted in reduced steady-state exposures to TEL and amprenavir. Coadministration is not recommended. | |||
| Concomitant administration of TEL and lopinavir/ritonavir resulted in reduced steady-state TEL exposure, while the steady-state exposure to lopinavir was not affected. Coadministration is not recommended. | |||
| Concomitant administration of TEL and efavirenz resulted in reduced steady-state exposures to TEL and efavirenz. | |||
| Concomitant administration of TEL and tenofovir resulted in increased tenofovir exposure. Increased clinical and laboratory monitoring are warranted. Tenofovir should be discontinued for patients who develop tenofovir-associated toxicities. | |||